{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:08:49Z","timestamp":1784891329096,"version":"3.55.0"},"reference-count":165,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>In the last few years research into Cannabis and its constituent phytocannabinoids has\nburgeoned, particularly in the potential application of novel cannabis phytochemicals for the treatment\nof diverse illnesses related to neurodegeneration and dementia, including Alzheimer\u2019s (AD),\nParkinson\u2019s (PD) and Huntington\u2019s disease (HD). To date, these neurological diseases have mostly\nrelied on symptomatological management. However, with an aging population globally, the search\nfor more efficient and disease-modifying treatments that could delay or mitigate disease progression\nis imperative. In this context, this review aims to present state of the art in the research with cannabinoids\nand novel cannabinoid-based drug candidates that have been emerged as novel promising\nalternatives for drug development and innovation in the therapeutics of a number of diseases, especially\nthose related to CNS-disturbance and impairment.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570159x18666200720172624","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T09:13:11Z","timestamp":1595322791000},"page":"449-464","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Phytocannabinoids: General Aspects and Pharmacological Potential in Neurodegenerative Diseases"],"prefix":"10.2174","volume":"19","author":[{"given":"Graziella","family":"dos Reis Rosa Franco","sequence":"first","affiliation":[{"name":"PeQuiM-Laboratory of Research in Medicinal Chemistry, Institute of Chemistry, Federal University of Alfenas, 37133- 840,Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Smid","sequence":"additional","affiliation":[{"name":"Discipline of Pharmacology, Adelaide Medical School, The University of Adelaide, South Australia, 5000,Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udio","family":"Viegas","sequence":"additional","affiliation":[{"name":"PeQuiM-Laboratory of Research in Medicinal Chemistry, Institute of Chemistry, Federal University of Alfenas, 37133- 840,Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","author":"Robison R.","year":"1999","unstructured":"Robison R.;  O Grande Livro Da Cannabis 1999","journal-title":"O Grande Livro Da Cannabis"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1152\/physrev.00002.2016","volume":"96","author":"Ligresti A.","year":"2016","unstructured":"Ligresti A.; De Petrocellis L.; Di Marzo V.; From phytocannabinoids to cannabinoid receptors and endocannabinoids: Pleiotropic physiological and pathological roles through complex pharmacology. Physiol Rev 2016,96(4),1593-1659","journal-title":"Physiol Rev"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.36607\/refacer.v5i1.3360","volume":"5","author":"Gontijo C.","year":"2016","unstructured":"Gontijo C.; Castro G.L.; De Castro A.D.; Canabidiol e suas aplica&#xE7;&#xF5;es terap&#xEA;uticas. Refacer 2016,5(1),1-9","journal-title":"Refacer"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3390\/medicines5040107","volume":"5","author":"Scherma M.","year":"2018","unstructured":"Scherma M.; Masia P.; Deidda M.; Fratta W.; Tanda G.; Fadda P.; New perspectives on the use of cannabis in the treatment of psychiatric disorders. Medicines 2018,5,107","journal-title":"Medicines"},{"key":"ref=5","year":"2017","unstructured":"National Academies of Sciences, Engineering, and Medicine The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research 2017","journal-title":"National Academies of Sciences, Engineering, and Medicine The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1055\/s-0043-124041","volume":"84","author":"Sexton M.","year":"2018","unstructured":"Sexton M.; Shelton K.; Haley P.; West M.; Evaluation of cannabinoid and terpenoid content: Cannabis flower compared to supercritical CO 2 concentrate. Planta Med 2018,84,4","journal-title":"Planta Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1039\/C5FO01281C","volume":"7","author":"Das S.","year":"2016","unstructured":"Das S.; Stark L.; Musgrave I.F.; Pukala T.; Smid S.D.; Bioactive polyphenol interactions with &#x3B2; amyloid: a comparison of binding modelling, effects on fibril and aggregate formation and neuroprotective capacity. Food Funct 2016,7(2),1138-1146","journal-title":"Food Funct"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fnint.2018.00051","volume":"12","author":"Russo E.B.","year":"2018","unstructured":"Russo E.B.; Cannabis therapeutics and the future of neurology. Front Integr Nuerosci 2018,12(October),51","journal-title":"Front Integr Nuerosci"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"S205","DOI":"10.1016\/S0924-977X(10)70232-7","volume":"20","author":"Pertwee R.","year":"2010","unstructured":"Pertwee R.; Pharmacological actions of cannabinoids. Eur Neuropsychopharmacol 2010,20,S205","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"13090","DOI":"10.1038\/s41598-018-31120-2","volume":"8","author":"Mudge E.M.","year":"2018","unstructured":"Mudge E.M.; Murch S.J.; Brown P.N.; Chemometric analysis of cannabinoids: chemotaxonomy and domestication syndrome. Sci Rep 2018,8(1),13090","journal-title":"Sci Rep"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"6091","DOI":"10.1021\/acsomega.7b00996","volume":"2","author":"Lewis M.M.","year":"2017","unstructured":"Lewis M.M.; Yang Y.; Wasilewski E.; Clarke H.A.; Kotra L.P.; Chemical profiling of medical cannabis extracts. ACS Omega 2017,2(9),6091-6103","journal-title":"ACS Omega"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1039\/C6NP00074F","volume":"33","author":"Hanu\u0161 L.O.","year":"2016","unstructured":"Hanu\u0161 L.O.; Meyer S.M.; Mu&#xF1;oz E.; Taglialatela-Scafati O.; Appendino G.; Phytocannabinoids: a unified critical inventory. Nat Prod Rep 2016,33(12),1357-1392","journal-title":"Nat Prod Rep"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.21577\/1984-6835.20170103","volume":"9","author":"Franco R.R.G.","year":"2017","unstructured":"Franco R.R.G.; Viegas Junior; The contribution of studies with canabidiol and synthetic analogues in the design of new drug candidates for neuropsychiatric disorders and neurodegenerative diseases. Rev Virtual Qu&#xED;mica 2017,9(4),1773-1798","journal-title":"Rev Virtual Qu&#xED;mica"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejim.2018.01.019","volume":"49","author":"Abuhasira R.","year":"2018","unstructured":"Abuhasira R.; Schleider L.B.L.; Mechoulam R.; Novack V.; Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. Eur J Intern Med 2018,49,44-50","journal-title":"Eur J Intern Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s13311-015-0375-5","volume":"12","author":"Rosenberg E.C.","year":"2015","unstructured":"Rosenberg E.C.; Tsien R.W.; Whalley B.J.; Devinsky O.; Cannabinoids and epilepsy. Neurotherapeutics 2015,12(4),747-768","journal-title":"Neurotherapeutics"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"412","DOI":"10.5740\/jaoacint.18-0208","volume":"102","author":"Klumpers L.E.","year":"2019","unstructured":"Klumpers L.E.; Thacker D.L.; A brief background on cannabis: From plant to medical indications. J AOAC Int 2019,102(2),412-420","journal-title":"J AOAC Int"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.pharmthera.2017.02.041","volume":"175","author":"Pisanti S.","year":"2017","unstructured":"Pisanti S.; Malfitano A.M.; Ciaglia E.; Lamberti A.; Ranieri R.; Cuomo G.; Abate M.; Faggiana G.; Proto M.C.; Fiore D.; Laezza C.; Bifulco M.; Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther 2017,175,133-150","journal-title":"Pharmacol Ther"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jep.2018.09.004","volume":"227","author":"Bonini S.A.","year":"2018","unstructured":"Bonini S.A.; Premoli M.; Tambaro S.; Kumar A.; Maccarinelli G.; Memo M.; Mastinu A.; Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. J Ethnopharmacol 2018,227,300-315","journal-title":"J Ethnopharmacol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.2174\/0929867325666180226095132","volume":"26","author":"P&#xE1;ez J.A.","year":"2019","unstructured":"P&#xE1;ez J.A.; Campillo N.E.; Innovative therapeutic potential of cannabinoid receptors as targets in Alzheimer\u2019s disease and less well-known diseases. Curr Med Chem 2019,26(18),3300-3340","journal-title":"Curr Med Chem"},{"key":"ref=20","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1691428]","volume":"2018","author":"Pellati F.","year":"2018","unstructured":"Pellati F.; Borgonetti V.; Brighenti V.; Biagi M.; Benvenuti S.; Corsi L.; Cannabis sativa L. and nonpsychoactive cannabinoids&#x202F;: their chemistry and role against oxidative stress, inflammation, and cancer. BioMed Res Int 2018,2018","journal-title":"BioMed Res Int"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.molmed.2019.11.002","volume":"26","author":"Maccarrone M.","year":"2019","unstructured":"Maccarrone M.; Missing pieces to the endocannabinoid puzzle. Trends Mol Med 2019,26(3),263-272","journal-title":"Trends Mol Med"},{"key":"ref=22","first-page":"328","volume":"83","author":"O&#x17C;arowski M.","year":"2016","unstructured":"O&#x17C;arowski M.; Mikolajczak P.\u0141.; Bogacz A.; Bartkowiak-Wieczorek J.; Kujawski R.; Majchrzycki M.; Wielgus K.; Seremak-Mrozikiewicz A.; Czerny B.; Progress in study of Cannabis sativa leaves extracts without psychotropic cannabinoids in animal model of neuropathic pain. J Med Sci 2016,83,328-335","journal-title":"J Med Sci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1590\/S1516-44462006000200015","volume":"28","author":"Zuardi A.W.","year":"2006","unstructured":"Zuardi A.W.; History of cannabis as a medicine: a review. Br J Psychiatry 2006,28(2),153-157","journal-title":"Br J Psychiatry"},{"key":"ref=24","volume":"44","year":"1961","unstructured":"Single Convention on Narcotic Drugs United Nations1961,44","journal-title":"Single Convention on Narcotic Drugs"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41570-017-0101","volume":"2","author":"Reekie T.A.","year":"2018","unstructured":"Reekie T.A.; Scott M.P.; Kassiou M.; The evolving science of phytocannabinoids. Nat Rev Chem 2018,2(1),1-12","journal-title":"Nat Rev Chem"},{"key":"ref=26","first-page":"41","volume":"1971","author":"Nations U.","year":"1971","unstructured":"Nations U.;  Convention on Psychotropic Substances 1971,1971,41","journal-title":"Convention on Psychotropic Substances"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.cbi.2018.07.018","volume":"293","author":"Maurya N.","year":"2018","unstructured":"Maurya N.; Velmurugan B.K.; Therapeutic applications of cannabinoids. Chem Biol Interact 2018,293,77-88","journal-title":"Chem Biol Interact"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.pharmthera.2018.10.006","volume":"195","author":"Bloomfield M.A.P.","year":"2019","unstructured":"Bloomfield M.A.P.; Hindocha C.; Green S.F.; Wall M.B.; Lees R.; Petrilli K.; Costello H.; Ogunbiyi M.O.; Bossong M.G.; Freeman T.P.; The neuropsychopharmacology of cannabis: A review of human imaging studies. Pharmacol Ther 2019,195,132-161","journal-title":"Pharmacol Ther"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"786","DOI":"10.21577\/1984-6835.20170049","volume":"9","author":"Matos R.L.A.","year":"2017","unstructured":"Matos R.L.A.; Spinola L.A.; Barboza L.L.; Garcia D.R.; Fran&#xE7;a T.C.C.; Affonso R.S.O.; Uso do canabidiol no tratamento da epilepsia. Rev Virtual Quim 2017,9(2),786-814","journal-title":"Rev Virtual Quim"},{"key":"ref=30","first-page":"62","volume":"Vol. 103","author":"Turner S.E.","year":"2017","unstructured":"Turner S.E.; Williams C.M.; Iversen L.; Whalley B.J.;  Phytocannabinoids Progress in the Chemistry of Organic Natural Products; Kinghorn, A; Falk, H; Gibbons, S 2017,Vol. 103,62-91","journal-title":"Phytocannabinoids Progress in the Chemistry of Organic Natural Products; Kinghorn, A; Falk, H; Gibbons, S"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.tips.2016.04.005","volume":"37","author":"Russo E.B.","year":"2016","unstructured":"Russo E.B.; Beyond cannabis: plants and the endocannabinoid system. Trends Pharmacol Sci 2016,37(7),594-605","journal-title":"Trends Pharmacol Sci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/978-3-319-45541-9_4","volume":"103","author":"Morales P.","year":"2017","unstructured":"Morales P.; Hurst D.P.; Reggio P.H.; Molecular targets of the phytocannabinoids: a complex picture. Prog Chem Org Nat Prod 2017,103,103-131","journal-title":"Prog Chem Org Nat Prod"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.tips.2016.12.004","volume":"38","author":"Russo E.B.","year":"2017","unstructured":"Russo E.B.; Cannabidiol claims and misconceptions. Trends Pharmacol Sci 2017,38(3),198-201","journal-title":"Trends Pharmacol Sci"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1177\/1934578X1801300922","volume":"13","author":"Pollastro F.","year":"2018","unstructured":"Pollastro F.; Caprioglio D.; Del Prete D.; Rogati F.; Minassi A.; Taglialatela-Scafati O.; Munoz E.; Appendino G.; Cannabichromene. Nat Prod Commun 2018,13,1189-1194","journal-title":"Nat Prod Commun"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1126\/science.169.3945.611","volume":"169","author":"Mechoulam R.","year":"1970","unstructured":"Mechoulam R.; Shani A.; Edery H.; Grunfeld Y.; Chemical basis of hashish activity. Science 1970,169(3945),611-612","journal-title":"Science"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1002\/cbdv.200790149","volume":"4","author":"Stern E.","year":"2007","unstructured":"Stern E.; Lambert D.M.; Medicinal chemistry endeavors around the phytocannabinoids. Chem Biodivers 2007,4(8),1707-1728","journal-title":"Chem Biodivers"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s13311-015-0374-6","volume":"12","author":"Di Marzo V.","year":"2015","unstructured":"Di Marzo V.; Piscitelli F.; The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics 2015,12(4),692-698","journal-title":"Neurotherapeutics"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.2174\/1568026616666160204122033","volume":"16","author":"Capasso A.","year":"2016","unstructured":"Capasso A.; Sobarzo-S&#xE1;nchez E.; Nabavi S.F.; Rastrelli L.; Cannabinoids for the treatment of schizophrenia: an overview. Curr Top Med Chem 2016,16(17),1916-1923","journal-title":"Curr Top Med Chem"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3389\/fphar.2018.00632","volume":"9","author":"Navarro G.","year":"2018","unstructured":"Navarro G.; Varani K.; Reyes-Resina I.; S&#xE1;nchez de Medina V.; Rivas-Santisteban R.; S&#xE1;nchez-Carnerero Callado C.; Vincenzi F.; Casano S.; Ferreiro-Vera C.; Canela E.I.; Borea P.A.; Nadal X.; Franco R.; Cannabigerol action at cannabinoid CB 1 and CB 2 receptors and at CB1-CB2 heteroreceptor complexes. Front Pharmacol 2018,9,632","journal-title":"Front Pharmacol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s13311-014-0304-z","volume":"12","author":"Valdeolivas S.","year":"2015","unstructured":"Valdeolivas S.; Navarrete C.; Cantarero I.; Bellido M.L.; Mu&#xF1;oz E.; Sagredo O.; Neuroprotective properties of cannabigerol in Huntington\u2019s disease: studies in R6\/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics 2015,12(1),185-199","journal-title":"Neurotherapeutics"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40035-019-0148-x","volume":"8","author":"Aguareles J.","year":"2019","unstructured":"Aguareles J.; Para&#xED;so-Luna J.; Palomares B.; Bajo-Gra&#xF1;eras R.; Navarrete C.; Ruiz-Calvo A.; Garc&#xED;a-Rinc&#xF3;n D.; Garc&#xED;a-Taboada E.; Guzm&#xE1;n M.; Mu&#xF1;oz E.; Galve-Roperh I.; Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration. Transl Neurodegener 2019,8,9","journal-title":"Transl Neurodegener"},{"key":"ref=42","first-page":"1","volume":"55","author":"Mammana S.","year":"2019","unstructured":"Mammana S.; Cavalli E.; Gugliandolo A.; Silvestro S.; Pollastro F.; Bramanti P.; Mazzon E.; Could the combination of two non-psychotropic cannabinoids counteract neuroinflammation? Effectiveness of cannabidiol associated with cannabigerol. Medicina (Kaunas) 2019,55(11),1-14","journal-title":"Medicina (Kaunas)"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules24142567","volume":"24","author":"Pinzi L.","year":"2019","unstructured":"Pinzi L.; Lherbet C.; Baltas M.; Pellati F.; Rastelli G.; In silico repositioning of cannabigerol as a novel inhibitor of the enoyl acyl carrier protein (ACP) reductase (INHA). Molecules 2019,24(14),1-9","journal-title":"Molecules"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"29789","DOI":"10.1038\/srep29789","volume":"6","author":"D&#xED;az-Alonso J.","year":"2016","unstructured":"D&#xED;az-Alonso J.; Para&#xED;so-Luna J.; Navarrete C.; Del R&#xED;o C.; Cantarero I.; Palomares B.; Aguareles J.; Fern&#xE1;ndez-Ruiz J.; Bellido M.L.; Pollastro F.; Appendino G.; Calzado M.A.; Galve-Roperh I.; Mu&#xF1;oz E.; VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington\u2019s disease. Sci Rep 2016,6,29789","journal-title":"Sci Rep"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms19071992","volume":"19","author":"Gugliandolo A.","year":"2018","unstructured":"Gugliandolo A.; Pollastro F.; Grassi G.; Bramanti P.; Mazzon E.; In vitro model of neuroinflammation: Efficacy of cannabigerol, a non-psychoactive cannabinoid. Int J Mol Sci 2018,19(7),1-16","journal-title":"Int J Mol Sci"},{"key":"ref=46","first-page":"20","volume":"1","author":"Mechoulam R.","year":"1966","unstructured":"Mechoulam R.; Gaoni Y.; Cannabichromene, a new active principle in hashish. Chem Commun 1966,1,20-21","journal-title":"Chem Commun"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.1111\/bph.14815","volume":"176","author":"Udoh M.","year":"2019","unstructured":"Udoh M.; Santiago M.; Devenish S.; McGregor I.S.; Connor M.; Cannabichromene is a cannabinoid CB2 receptor agonist. Br J Pharmacol 2019,176(23),4537-4547","journal-title":"Br J Pharmacol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ntt.2014.09.003","volume":"46","author":"Rosenthaler S.","year":"2014","unstructured":"Rosenthaler S.; P&#xF6;hn B.; Kolmanz C.; Huu C.N.; Krewenka C.; Huber A.; Kranner B.; Rausch W.D.; Moldzio R.; Differences in receptor binding affinity of several phytocannabinoids do not explain their effects on neural cell cultures. Neurotoxicol Teratol 2014,46,49-56","journal-title":"Neurotoxicol Teratol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/0306-3623(81)90090-2","volume":"12","author":"Hatoum N.S.","year":"1981","unstructured":"Hatoum N.S.; Davis W.M.; Elsohly M.A.; Turner C.E.; Cannabichromene and delta 9-tetrahydrocannabinol: interactions relative to lethality, hypothermia and hexobarbital hypnosis. Gen Pharmacol 1981,12(5),357-362","journal-title":"Gen Pharmacol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/jps.2600691136","volume":"69","author":"Wirth P.W.","year":"1980","unstructured":"Wirth P.W.; Watson E.S.; ElSohly M.A.; Seidel R.; Murphy J.C.; Turner C.E.; Anti-inflammatory activity of cannabichromene homologs. J Pharm Sci 1980,69(11),1359-1360","journal-title":"J Pharm Sci"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1124\/jpet.117.244368","volume":"365","author":"Petrosino S.","year":"2018","unstructured":"Petrosino S.; Verde R.; Vaia M.; Allar&#xE0; M.; Iuvone T.; Di Marzo V.; Anti-inflammatory properties of cannabidiol, a nonpsychotropic cannabinoid, in experimental allergic contact dermatitis. J Pharmacol Exp Ther 2018,365(3),652-663","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=52","author":"Iuvone T.","year":"2012","unstructured":"Iuvone T.; Di Marzo V.; Guy G.; Wright S.; Stott C.; Cannabinoids for use in the treatment of neurodegenative diseases or disorders UK Patent Application GB 2492487 2012"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"7719","DOI":"10.1007\/s12035-019-1637-8","volume":"56","author":"Schubert D.","year":"2019","unstructured":"Schubert D.; Kepchia D.; Liang Z.; Dargusch R.; Goldberg J.; Maher P.; Efficacy of cannabinoids in a pre-clinical drug-screening platform for Alzheimer\u2019s disease. Mol Neurobiol 2019,56(11),7719-7730","journal-title":"Mol Neurobiol"},{"key":"ref=54","first-page":"1","volume":"11","author":"Breuer A.","year":"2016","unstructured":"Breuer A.; Haj C.G.; Foga&#xE7;a M.V.; Gomes F.V.; Silva N.R.; Pedrazzi J.F.; Del Bel E.A.; Hallak J.C.; Crippa J.A.; Zuardi A.W.; Mechoulam R.; Guimar&#xE3;es F.S.; Fluorinated cannabidiol derivatives: Enhancement of activity in mice models predictive of anxiolytic, antidepressant and antipsychotic effects. PLoS One 2016,11,1-19","journal-title":"PLoS One"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1021\/ja01858a058","volume":"62","author":"Adams R.","year":"1939","unstructured":"Adams R.; Hunt M.; Clark J.H.; Structure of cannabidiol, a product isolated from the marihuana extract of minnesota wild hemp. I. J Am Chem Soc 1939,62,196-200","journal-title":"J Am Chem Soc"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/0040-4020(63)85022-X","volume":"19","author":"Mechoulam R.","year":"1963","unstructured":"Mechoulam R.; Shvo Y.; Hashish I.; The structure of cannabidiol. Tetrahedron 1963,19(12),2073-2078","journal-title":"Tetrahedron"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/FBP.0000000000000247","volume":"28","author":"Karl T.","year":"2017","unstructured":"Karl T.; Garner B.; Cheng D.; The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer\u2019s disease. Behav Pharmacol 2017,28(2 and 3-Spec Issue),142-160","journal-title":"Behav Pharmacol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","volume":"172","author":"Laprairie R.B.","year":"2015","unstructured":"Laprairie R.B.; Bagher A.M.; Kelly M.E.M.; Denovan-Wright E.M.; Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 2015,172(20),4790-4805","journal-title":"Br J Pharmacol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2174\/1874467212666190215112036","volume":"12","author":"Ye L.","year":"2019","unstructured":"Ye L.; Cao Z.; Wang W.; Zhou N.; New insights in cannabinoid receptor structure and signaling. Curr Mol Pharmacol 2019,12(3),239-248","journal-title":"Curr Mol Pharmacol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nrd.2018.115","volume":"17","author":"Di Marzo V.","year":"2018","unstructured":"Di Marzo V.; New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov 2018,17(9),623-639","journal-title":"Nat Rev Drug Discov"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1111\/bph.13497","volume":"173","author":"O\u2019Sullivan S.E.","year":"2016","unstructured":"O\u2019Sullivan S.E.; An update on PPAR activation by cannabinoids. Br J Pharmacol 2016,173(12),1899-1910","journal-title":"Br J Pharmacol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1476-5381.2008.00046.x","volume":"156","author":"Resstel L.B.M.","year":"2009","unstructured":"Resstel L.B.M.; Tavares R.F.; Lisboa S.F.S.; Joca S.R.L.; Corr&#xEA;a F.M.A.; Guimar&#xE3;es F.S.; 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol 2009,156(1),181-188","journal-title":"Br J Pharmacol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000362689","volume":"94","author":"Cheng Y.","year":"2014","unstructured":"Cheng Y.; Dong Z.; Liu S.; &#x3B2;-Caryophyllene ameliorates the Alzheimer-like phenotype in APP\/PS1 Mice through CB2 receptor activation and the PPAR&#x3B3; pathway. Pharmacology 2014,94(1-2),1-12","journal-title":"Pharmacology"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1471-4159.2003.02327.x","volume":"89","author":"Iuvone T.","year":"2004","unstructured":"Iuvone T.; Esposito G.; Esposito R.; Santamaria R.; Di Rosa M.; Izzo A.A.; Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on &#x3B2;-amyloid-induced toxicity in PC12 cells. J Neurochem 2004,89(1),134-141","journal-title":"J Neurochem"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fphar.2017.00020","volume":"8","author":"Watt G.","year":"2017","unstructured":"Watt G.; Karl T.; In vivo evidence for therapeutic properties of cannabidiol (CBD) for Alzheimer\u2019s disease. Front Pharmacol 2017,8,20","journal-title":"Front Pharmacol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10571-013-9984-x","volume":"34","author":"Janefjord E.","year":"2014","unstructured":"Janefjord E.; M&#xE5;&#xE5;g J.L.V.; Harvey B.S.; Smid S.D.; Cannabinoid effects on &#x3B2; amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro. Cell Mol Neurobiol 2014,34(1),31-42","journal-title":"Cell Mol Neurobiol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms18010026","volume":"18","author":"Libro R.","year":"2016","unstructured":"Libro R.; Diomede F.; Scionti D.; Piattelli A.; Grassi G.; Pollastro F.; Bramanti P.; Mazzon E.; Trubiani O.; Cannabidiol modulates the expression of alzheimer\u2019s disease-related genes in mesenchymal stem cells. Int J Mol Sci 2016,18(1),1-19","journal-title":"Int J Mol Sci"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1097\/QAD.0000000000002345","volume":"33","author":"Costiniuk C.T.","year":"2019","unstructured":"Costiniuk C.T.; Jenabian M.A.; Cannabinoids and inflammation: implications for people living with HIV. AIDS 2019,33(15),2273-2288","journal-title":"AIDS"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/ptr.5095","volume":"28","author":"Scuderi C.","year":"2014","unstructured":"Scuderi C.; Steardo L.; Esposito G.; Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPAR&#x3B3; involvement. Phytother Res 2014,28(7),1007-1013","journal-title":"Phytother Res"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0028668","volume":"6","author":"Esposito G.","year":"2011","unstructured":"Esposito G.; Scuderi C.; Valenza M.; Togna G.I.; Latina V.; de Filippis D.; Cipriano M.; Carrat&#xF9; M.R.; Iuvone T.; Steardo L.; Cannabidiol reduces A&#x3B2;-induced neuroinflammation and promotes hippocampal neurogenesis through PPAR&#x3B3; involvement. PLoS One 2011,6,1-8","journal-title":"PLoS One"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1093\/abbs\/gmx073","volume":"49","author":"Vall&#xE9;e A.","year":"2017","unstructured":"Vall&#xE9;e A.; Lecarpentier Y.; Guillevin R.; Vall&#xE9;e J.N.; Effects of cannabidiol interactions with Wnt\/&#x3B2;-catenin pathway and PPAR&#x3B3; on oxidative stress and neuroinflammation in Alzheimer\u2019s disease. Acta Biochim Biophys Sin (Shanghai) 2017,49(10),853-866","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1124\/mol.111.071290","volume":"79","author":"Mart&#xED;n-Moreno A.M.","year":"2011","unstructured":"Mart&#xED;n-Moreno A.M.; Reigada D.; Ram&#xED;rez B.G.; Mechoulam R.; Innamorato N.; Cuadrado A.; de Ceballos M.L.; Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer\u2019s disease. Mol Pharmacol 2011,79(6),964-973","journal-title":"Mol Pharmacol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00406-019-00982-6","volume":"269","author":"Crippa J.A.S.","year":"2019","unstructured":"Crippa J.A.S.; Hallak J.E.C.; Zuardi A.W.; Guimar&#xE3;es F.S.; Tumas V.; Dos Santos R.G.; Is cannabidiol the ideal drug to treat non-motor Parkinson\u2019s disease symptoms? Eur Arch Psychiatry Clin Neurosci 2019,269(1),121-133","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.lfs.2019.03.053","volume":"224","author":"Premoli M.","year":"2019","unstructured":"Premoli M.; Aria F.; Bonini S.A.; Maccarinelli G.; Gianoncelli A.; Pina S.D.; Tambaro S.; Memo M.; Mastinu A.; Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment. Life Sci 2019,224,120-127","journal-title":"Life Sci"},{"key":"ref=75","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107808]","volume":"163","author":"Crivelaro do Nascimento G.","year":"2020","unstructured":"Crivelaro do Nascimento G.; Ferrari D.P.; Guimaraes F.S.; Del Bel E.A.; Bortolanza M.; Ferreira-Junior N.C.; Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson\u2019s disease. Neuropharmacology 2020,163","journal-title":"Neuropharmacology"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3389\/fphar.2016.00343","volume":"7","author":"Peres F.F.","year":"2016","unstructured":"Peres F.F.; Levin R.; Suiama M.A.; Diana M.C.; Gouv&#xEA;a D.A.; Almeida V.; Santos C.M.; Lungato L.; Zuardi A.W.; Hallak J.E.C.; Crippa J.A.; V&#xE2;nia D.; Silva R.H.; Ab&#xED;lio V.C.; Cannabidiol prevents motor and cognitive impairments induced by reserpine in rats. Front Pharmacol 2016,7,343","journal-title":"Front Pharmacol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1039\/C9AN00890J","volume":"144","author":"Hacke A.C.M.","year":"2019","unstructured":"Hacke A.C.M.; Lima D.; de Costa F.; Deshmukh K.; Li N.; Chow A.M.; Marques J.A.; Pereira R.P.; Kerman K.; Probing the antioxidant activity of \u03949-tetrahydrocannabinol and cannabidiol in Cannabis sativa extracts. Analyst (Lond) 2019,144(16),4952-4961","journal-title":"Analyst (Lond)"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"974","DOI":"10.2174\/1570159X17666190603171901","volume":"17","author":"Huestis M.A.","year":"2019","unstructured":"Huestis M.A.; Solimini R.; Pichini S.; Pacifici R.; Carlier J.; Busard&#xF2; F.P.; Cannabidiol adverse effects and toxicity. Curr Neuropharmacol 2019,17(10),974-989","journal-title":"Curr Neuropharmacol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/bcp.13710","volume":"84","author":"Lucas C.J.","year":"2018","unstructured":"Lucas C.J.; Galettis P.; Schneider J.; The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol 2018,84(11),2477-2482","journal-title":"Br J Clin Pharmacol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules25030631","volume":"25","author":"Izzo L.","year":"2020","unstructured":"Izzo L.; Castaldo L.; Narv&#xE1;ez A.; Graziani G.; Gaspari A.; Rodr&#xED;guez-Carrasco Y.; Ritieni A.; Analysis of phenolic compounds in commercial Cannabis sativa L. Inflorescences Using UHPLC-Q-Orbitrap HRMS. Molecules 2020,25(3),1-12","journal-title":"Molecules"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1021\/acsmedchemlett.6b00009","volume":"7","author":"Kinney W.A.","year":"2016","unstructured":"Kinney W.A.; McDonnell M.E.; Zhong H.M.; Liu C.; Yang L.; Ling W.; Qian T.; Chen Y.; Cai Z.; Petkanas D.; Brenneman D.E.; Discovery of KLS-13019, a cannabidiol-derived neuroprotective agent, with improved potency, safety, and permeability. ACS Med Chem Lett 2016,7(4),424-428","journal-title":"ACS Med Chem Lett"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.pnpbp.2015.05.010","volume":"64","author":"Velasco G.","year":"2016","unstructured":"Velasco G.; Hern&#xE1;ndez-Tiedra S.; D&#xE1;vila D.; Lorente M.; The use of cannabinoids as anticancer agents. Prog Neuropsychopharmacol Biol Psychiatry 2016,64,259-266","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.archoralbio.2019.05.028","volume":"104","author":"Wong H.","year":"2019","unstructured":"Wong H.; Cairns B.E.; Cannabidiol, cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain. Arch Oral Biol 2019,104,33-39","journal-title":"Arch Oral Biol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1002\/ejp.1085","volume":"21","author":"Wong H.","year":"2017","unstructured":"Wong H.; Hossain S.; Cairns B.E.; Delta-9-tetrahydrocannabinol decreases masticatory muscle sensitization in female rats through peripheral cannabinoid receptor activation. Eur J Pain 2017,21(10),1732-1742","journal-title":"Eur J Pain"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1365-2990.2011.01248.x","volume":"38","author":"Carroll C.B.","year":"2012","unstructured":"Carroll C.B.; Zeissler M.L.; Hanemann C.O.; Zajicek J.P.\u0394.\u0394.; \n-tetrahydrocannabinol (\u0394-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson\u2019s disease. Neuropathol Appl Neurobiol 2012,38(6),535-547","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1002\/ptr.5712","volume":"30","author":"Nguyen C.H.","year":"2016","unstructured":"Nguyen C.H.; Krewenka C.; Radad K.; Kranner B.; Huber A.; Duvigneau J.C.; Miller I.; Moldzio R.; THC (\u03949-Tetrahydrocannabinol) exerts neuroprotective effect in glutamate-affected murine primary mesencephalic cultures through restoring mitochondrial membrane potential and anti-apoptosis involving CB1 receptor-dependent mechanism. Phytother Res 2016,30(12),2044-2052","journal-title":"Phytother Res"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.cell.2013.10.042","volume":"155","author":"Chen R.","year":"2013","unstructured":"Chen R.; Zhang J.; Fan N.; Teng Z.Q.; Wu Y.; Yang H.; Tang Y.P.; Sun H.; Song Y.; Chen C.\u0394.; 9-THC-caused synaptic and memory impairments are mediated through COX-2 signaling. Cell 2013,155(5),1154-1165","journal-title":"Cell"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3233\/JAD-141014","volume":"43","author":"Aso E.","year":"2015","unstructured":"Aso E.; S&#xE1;nchez-Pla A.; Vegas-Lozano E.; Maldonado R.; Ferrer I.; Cannabis-based medicine reduces multiple pathological processes in A&#x3B2;PP\/PS1 mice. J Alzheimers Dis 2015,43(3),977-991","journal-title":"J Alzheimers Dis"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/nm.4311","volume":"23","author":"Bilkei-Gorzo A.","year":"2017","unstructured":"Bilkei-Gorzo A.; Albayram O.; Draffehn A.; Michel K.; Piyanova A.; Oppenheimer H.; Dvir-Ginzberg M.; R&#xE1;cz I.; Ulas T.; Imbeault S.; Bab I.; Schultze J.L.; Zimmer A.; A chronic low dose of \u03949-tetrahydrocannabinol (THC) restores cognitive function in old mice. Nat Med 2017,23(6),782-787","journal-title":"Nat Med"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/bph.12944","volume":"172","author":"McPartland J.M.","year":"2015","unstructured":"McPartland J.M.; Duncan M.; Di Marzo V.; Pertwee R.G.; Are cannabidiol and \u0394(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol 2015,172(3),737-753","journal-title":"Br J Pharmacol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/j.1476-5381.2011.01278.x","volume":"163","author":"Garc&#xED;a C.","year":"2011","unstructured":"Garc&#xED;a C.; Palomo-Garo C.; Garc&#xED;a-Arencibia M.; Ramos J.; Pertwee R.; Fern&#xE1;ndez-Ruiz J.; Symptom-relieving and neuroprotective effects of the phytocannabinoid \u0394-THCV in animal models of Parkinson\u2019s disease. Br J Pharmacol 2011,163(7),1495-1506","journal-title":"Br J Pharmacol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.phrs.2018.08.021","volume":"136","author":"Janssens A.","year":"2018","unstructured":"Janssens A.; Silvestri C.; Martella A.; Vanoevelen J.M.; Di Marzo V.; Voets T.\u0394.; 9-tetrahydrocannabivarin impairs epithelial calcium transport through inhibition of TRPV5 and TRPV6. Pharmacol Res 2018,136,83-89","journal-title":"Pharmacol Res"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00213-011-2415-0","volume":"219","author":"Deiana S.","year":"2012","unstructured":"Deiana S.; Watanabe A.; Yamasaki Y.; Amada N.; Arthur M.; Fleming S.; Woodcock H.; Dorward P.; Pigliacampo B.; Close S.; Platt B.; Riedel G.; Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), \u0394-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl) 2012,219(3),859-873","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0021-9673(01)94980-5","volume":"74","author":"Vree T.B.","year":"1972","unstructured":"Vree T.B.; Breimer D.D.; van Ginneken C.A.M.; van Rossum J.M.; Identification of cannabicyclol with a pentyl or propyl side-chain by means of combined gas chromatography-mass spectrometry. J Chromatogr A 1972,74(1),124-127","journal-title":"J Chromatogr A"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1016\/S0040-4039(01)97472-6","volume":"216","author":"Kane V.V.","year":"1971","unstructured":"Kane V.V.; Structure of cannabicyclol, a detailed NMR study of a synthetic analog. Tetrahedron Lett 1971,216,4101-4104","journal-title":"Tetrahedron Lett"},{"key":"ref=96","first-page":"90","volume":"13","author":"Korte F.","year":"1964","unstructured":"Korte F.; Sieper H.; Zur chemischen Klassifizierung von Pflanzen, XX Isolierung von Haschisch\u2010inhaltsstoffen Aus Cannabis Sativa non Indica. Justus Liebigs Ann Chem 1964,13,90-98","journal-title":"Justus Liebigs Ann Chem"},{"key":"ref=97","first-page":"833","volume":"34","author":"Yamamoto I.","year":"1988","unstructured":"Yamamoto I.; Gohda H.; Narimatsu S.; Yoshimura H.; Identification of cannabielsoin, a new metabolite of cannabidiol formed by guinea-pig hepatic microsomal enzymes, and its pharmacological activity in mice. Chem Pharm Bull (Tokyo) 1988,34,833-838","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/S0040-4020(01)97114-5","volume":"30","author":"Shani A.","year":"1974","unstructured":"Shani A.; Mechoulam R.; Cannabielsoic acids. Isolation and synthesis by a novel oxidative cyclization. Tetrahedron 1974,30,2437-2446","journal-title":"Tetrahedron"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1271\/bbb1961.30.619","volume":"30","author":"Obata Y.","year":"1966","unstructured":"Obata Y.; Ishikawa Y.; Studies on the constituents of hemp plant (cannabis sativa l.). Agric Biol Chem 1966,30,619-620","journal-title":"Agric Biol Chem"},{"key":"ref=100","first-page":"283","volume":"7","author":"Chan W.R.","year":"1975","unstructured":"Chan W.R.; Magnus K.E.; Watson H.A.; The strucuture of cannabitriol. Specialia 1975,7,283-284","journal-title":"Specialia"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1146\/annurev-pharmtox-010818-021441","volume":"60","author":"Pacher P.","year":"2020","unstructured":"Pacher P.; Kogan N.M.; Mechoulam R.; Beyond THC and endocannabinoids. Annu Rev Pharmacol Toxicol 2020,60,637-659","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3389\/fphar.2020.00124","volume":"11","author":"Cassano T.","year":"2020","unstructured":"Cassano T.; Villani R.; Pace L.; Carbone A.; Bukke V.N.; Orkisz S.; Avolio C.; Serviddio G.; From Cannabis sativa to Cannabidiol: Promising therapeutic candidate for the treatment of neurodegenerative diseases. Front Pharmacol 2020,11,124","journal-title":"Front Pharmacol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3233\/JAD-130137","volume":"35","author":"Aso E.","year":"2013","unstructured":"Aso E.; Juv&#xE9;s S.; Maldonado R.; Ferrer I.; CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in A&#x3B2;PP\/PS1 mice. J Alzheimers Dis 2013,35(4),847-858","journal-title":"J Alzheimers Dis"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1590\/S1516-44462008000300015","volume":"30","author":"Zuardi A.W.","year":"2008","unstructured":"Zuardi A.W.; Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Br J Psychiatry 2008,30(3),271-280","journal-title":"Br J Psychiatry"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2174\/187152711794480483","volume":"10","author":"Campos H.C.","year":"2011","unstructured":"Campos H.C.; da Rocha M.D.; Viegas F.P.D.; Nicastro P.C.; Fossaluzza P.C.; Fraga C.A.M.; Barreiro E.J.; Viegas C.; The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders I: Parkinson\u2019s disease. CNS Neurol Disord Drug Targets 2011,10(2),239-250","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nature20153","volume":"539","author":"Bloomfield M.A.P.","year":"2016","unstructured":"Bloomfield M.A.P.; Ashok A.H.; Volkow N.D.; Howes O.D.; The effects of \u03949-tetrahydrocannabinol on the dopamine system. Nature 2016,539(7629),369-377","journal-title":"Nature"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/dta.1425","volume":"5","author":"Deiana S.","year":"2013","unstructured":"Deiana S.; Medical use of cannabis. Cannabidiol: a new light for schizophrenia? Drug Test Anal 2013,5(1),46-51","journal-title":"Drug Test Anal"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.neuroscience.2016.10.031","volume":"340","author":"Sartim A.G.","year":"2017","unstructured":"Sartim A.G.; Moreira F.A.; Joca S.R.L.; Involvement of CB1 and TRPV1 receptors located in the ventral medial prefrontal cortex in the modulation of stress coping behavior. Neuroscience 2017,340,126-134","journal-title":"Neuroscience"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pnpbp.2018.06.002","volume":"86","author":"Sales A.J.","year":"2018","unstructured":"Sales A.J.; Crestani C.C.; Guimar&#xE3;es F.S.; Joca S.R.L.; Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels. Prog Neuropsychopharmacol Biol Psychiatry 2018,86,255-261","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1111\/bph.14019","volume":"174","author":"Nadal X.","year":"2017","unstructured":"Nadal X.; Del R&#xED;o C.; Casano S.; Palomares B.; Ferreiro-Vera C.; Navarrete C.; S&#xE1;nchez-Carnerero C.; Cantarero I.; Bellido M.L.; Meyer S.; Morello G.; Appendino G.; Mu&#xF1;oz E.; Tetrahydrocannabinolic acid is a potent PPAR&#x3B3; agonist with neuroprotective activity. Br J Pharmacol 2017,174(23),4263-4276","journal-title":"Br J Pharmacol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.brainres.2014.09.008","volume":"1617","author":"Doty K.R.","year":"2015","unstructured":"Doty K.R.; Guillot-Sestier M.V.; Town T.; The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive? Brain Res 2015,1617,155-173","journal-title":"Brain Res"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1134\/S0006297918090122","volume":"83","author":"Aliseychik M.P.","year":"2018","unstructured":"Aliseychik M.P.; Andreeva T.V.; Rogaev E.I.; Immunogenetic Factors of Neurodegenerative Diseases: The Role of HLA Class II. Biochemistry (Mosc) 2018,83(9),1104-1116","journal-title":"Biochemistry (Mosc)"},{"key":"ref=113","first-page":"1","volume":"19","author":"Zou S.","year":"2018","unstructured":"Zou S.; Kumar U.; Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. Int J Mol Sci 2018,19(3),1-23","journal-title":"Int J Mol Sci"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijdevneu.2019.03.002","volume":"76","author":"Zou M.","year":"2019","unstructured":"Zou M.; Li D.; Li L.; Wu L.; Sun C.; Role of the endocannabinoid system in neurological disorders. Int J Dev Neurosci 2019,76,95-102","journal-title":"Int J Dev Neurosci"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.phrs.2016.07.021","volume":"111","author":"Bisogno T.","year":"2016","unstructured":"Bisogno T.; Oddi S.; Piccoli A.; Fazio D.; Maccarrone M.; Type-2 cannabinoid receptors in neurodegeneration. Pharmacol Res 2016,111,721-730","journal-title":"Pharmacol Res"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.plipres.2016.02.002","volume":"62","author":"Iannotti F.A.","year":"2016","unstructured":"Iannotti F.A.; Di Marzo V.; Petrosino S.; Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. Prog Lipid Res 2016,62,107-128","journal-title":"Prog Lipid Res"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/CCO.0000000000000523","volume":"31","author":"Lossignol D.","year":"2019","unstructured":"Lossignol D.; Cannabinoids: a new approach for pain control? Curr Opin Oncol 2019,31(4),275-279","journal-title":"Curr Opin Oncol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1124\/pr.110.003004","volume":"62","author":"Pertwee R.G.","year":"2010","unstructured":"Pertwee R.G.; Howlett A.C.; Abood M.E.; Alexander S.P.H.; Di Marzo V.; Elphick M.R.; Greasley P.J.; Hansen H.S.; Kunos G.; Cannabinoid receptors and their ligands&#x202F;: beyond cb 1 and cb 2. Pharmacol Rev 2010,62,588-631","journal-title":"Pharmacol Rev"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/nature20613","volume":"540","author":"Shao Z.","year":"2016","unstructured":"Shao Z.; Yin J.; Chapman K.; Grzemska M.; Clark L.; Wang J.; Rosenbaum D.M.; High-resolution crystal structure of the human CB1 cannabinoid receptor. Nature 2016,540(7634),602-606","journal-title":"Nature"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.cell.2016.10.004","volume":"167","author":"Hua T.","year":"2016","unstructured":"Hua T.; Vemuri K.; Pu M.; Qu L.; Han G.W.; Wu Y.; Zhao S.; Shui W.; Li S.; Korde A.; Laprairie R.B.; Stahl E.L.; Ho J.H.; Zvonok N.; Zhou H.; Kufareva I.; Wu B.; Zhao Q.; Hanson M.A.; Bohn L.M.; Makriyannis A.; Stevens R.C.; Liu Z.J.; Crystal structure of the human cannabinoid receptor CB1. Cell 2016,167(3),750-762.e14","journal-title":"Cell"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.cell.2018.12.011","volume":"176","author":"Li X.","year":"2019","unstructured":"Li X.; Hua T.; Vemuri K.; Ho J.H.; Wu Y.; Wu L.; Popov P.; Benchama O.; Zvonok N.; Locke K.; Qu L.; Han G.W.; Iyer M.R.; Cinar R.; Coffey N.J.; Wang J.; Wu M.; Katritch V.; Zhao S.; Kunos G.; Bohn L.M.; Makriyannis A.; Stevens R.C.; Liu Z.J.; Crystal structure of the human cannabinoid receptor cb2. Cell 2019,176(3),459-467.e13","journal-title":"Cell"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.disamonth.2016.05.014","volume":"62","author":"Temple L.M.","year":"2016","unstructured":"Temple L.M.; Medical marijuana and pain management. Dis Mon 2016,62(9),346-352","journal-title":"Dis Mon"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41401-019-0210-3","volume":"40","author":"Wu J.","year":"2019","unstructured":"Wu J.; Cannabis, cannabinoid receptors, and endocannabinoid system: yesterday, today, and tomorrow. Acta Pharmacol Sin 2019,40(3),297-299","journal-title":"Acta Pharmacol Sin"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1111\/febs.12125","volume":"280","author":"D\u2019Addario C.","year":"2013","unstructured":"D\u2019Addario C.; Di Francesco A.; Pucci M.; Finazzi Agr&#xF2; A.; Maccarrone M.; Epigenetic mechanisms and endocannabinoid signalling. FEBS J 2013,280(9),1905-1917","journal-title":"FEBS J"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.plefa.2018.11.016","volume":"140","author":"Chanda D.","year":"2019","unstructured":"Chanda D.; Neumann D.; Glatz J.F.C.; The endocannabinoid system: Overview of an emerging multi-faceted therapeutic target. Prostaglandins Leukot Essent Fatty Acids 2019,140,51-56","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1089\/ars.2017.7144","volume":"29","author":"Paloczi J.","year":"2018","unstructured":"Paloczi J.; Varga Z.V.; Hasko G.; Pacher P.; Neuroprotection in Oxidative stress-related neurodegenerative diseases: role of endocannabinoid system modulation. Antioxid Redox Signal 2018,29(1),75-108","journal-title":"Antioxid Redox Signal"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"12866","DOI":"10.1038\/s41598-019-49177-y","volume":"9","author":"Nielsen J.E.","year":"2019","unstructured":"Nielsen J.E.; Rolland A.D.; Rajpert-De Meyts E.; Janfelt C.; J&#xF8;rgensen A.; Winge S.B.; Kristensen D.M.; Juul A.; Chalmel F.; J&#xE9;gou B.; Skakkebaek N.E.; Characterisation and localisation of the endocannabinoid system components in the adult human testis. Sci Rep 2019,9(1),12866","journal-title":"Sci Rep"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.smim.2014.04.002","volume":"26","author":"Malfitano A.M.","year":"2014","unstructured":"Malfitano A.M.; Basu S.; Maresz K.; Bifulco M.; Dittel B.N.; What we know and do not know about the cannabinoid receptor 2 (CB2). Semin Immunol 2014,26(5),369-379","journal-title":"Semin Immunol"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1590\/S0047-20852011000200006","volume":"60","author":"Luis J.","year":"2011","unstructured":"Luis J.; Costa G.P.; Maia L.O.; Villares J.C.; Fernandez M.; Neurobiology of cannabis: from the endocannabinoid system to cannabis-related disorder. J Bras Psiquiatr 2011,60,111-122","journal-title":"J Bras Psiquiatr"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fnbeh.2012.00009","volume":"6","author":"Battista N.","year":"2012","unstructured":"Battista N.; Di Tommaso M.; Bari M.; Maccarrone M.; The endocannabinoid system: an overview. Front Behav Neurosci 2012,6,9","journal-title":"Front Behav Neurosci"},{"key":"ref=131","first-page":"53","author":"Fezza F.","year":"2014","unstructured":"Fezza F.; Maccarrone M.; Endocannabinoid biochemistry: What do we know after 50 years? Cannabinoids, 1st ed; Di Marzo, V., Ed.;  John Wiley  2014,53-94","journal-title":"John Wiley"},{"key":"ref=132","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2019.109745]","volume":"96","author":"Han Q-W.","year":"2020","unstructured":"Han Q-W.; Yuan Y-H.; Chen N-H.; The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson\u2019s disease. Prog Neuropsychopharmacol Biol Psychiatry 2020,96","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/nrd2553","volume":"7","author":"Di Marzo V.","year":"2008","unstructured":"Di Marzo V.; Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008,7(5),438-455","journal-title":"Nat Rev Drug Discov"},{"key":"ref=134","first-page":"pp 31","volume":"80","author":"Fowler C.J.","year":"2017","unstructured":"Fowler C.J.; Doherty P.; Alexander S.P.H.; endocannabinoid turnover in advances in pharmacolology. Elsevier Inc 2017,80,pp 31-66","journal-title":"Elsevier Inc"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fpls.2016.00019","volume":"7","author":"Andre C.M.","year":"2016","unstructured":"Andre C.M.; Hausman J.F.; Guerriero G.; Cannabis sativa: The plant of the thousand and one molecules. Front Plant Sci 2016,7,19","journal-title":"Front Plant Sci"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1021\/acs.jnatprod.6b01126","volume":"80","author":"Allegrone G.","year":"2017","unstructured":"Allegrone G.; Pollastro F.; Magagnini G.; Taglialatela-Scafati O.; Seegers J.; Koeberle A.; Werz O.; Appendino G.; The Bibenzyl canniprene inhibits the production of pro-inflammatory eicosanoids and selectively accumulates in some cannabis sativa strains. J Nat Prod 2017,80(3),731-734","journal-title":"J Nat Prod"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"10512","DOI":"10.1523\/JNEUROSCI.5183-12.2013","volume":"33","author":"Valera E.","year":"2013","unstructured":"Valera E.; Dargusch R.; Maher P.A.; Schubert D.; Modulation of 5-lipoxygenase in proteotoxicity and Alzheimer\u2019s disease. J Neurosci 2013,33(25),10512-10525","journal-title":"J Neurosci"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/0006-2952(85)90325-9","volume":"34","author":"Barrett M.L.","year":"1985","unstructured":"Barrett M.L.; Gordon D.; Evans F.J.; Isolation from Cannabis sativa L. of cannflavin--a novel inhibitor of prostaglandin production. Biochem Pharmacol 1985,34(11),2019-2024","journal-title":"Biochem Pharmacol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.phanu.2014.05.001","volume":"2","author":"Werz O.","year":"2014","unstructured":"Werz O.; Seegers J.; Schaible A.M.; Weinigel C.; Barz D.; Koeberle A.; Allegrone G.; Pollastro F.; Zampieri L.; Grassi G.; Appendino G.; Cannflavins from hemp sprouts, a novel cannabinoid-free hemp food product, target microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. PharmaNutrition 2014,2,53-60","journal-title":"PharmaNutrition"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1016\/j.bmc.2017.05.041","volume":"25","author":"Marsh D.T.","year":"2017","unstructured":"Marsh D.T.; Das S.; Ridell J.; Smid S.D.; Structure-activity relationships for flavone interactions with amyloid &#x3B2; reveal a novel anti-aggregatory and neuroprotective effect of 2\u2032,3\u2032,4\u2032-trihydroxy-flavone (2-D08). Bioorg Med Chem 2017,25(14),3827-3834","journal-title":"Bioorg Med Chem"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"7710","DOI":"10.1073\/pnas.0910723107","volume":"107","author":"Bieschke J.","year":"2010","unstructured":"Bieschke J.; Russ J.; Friedrich R.P.; Ehrnhoefer D.E.; Wobst H.; Neugebauer K.; Wanker E.E.; EGCG remodels mature &#x3B1;-synuclein and amyloid-&#x3B2; fibrils and reduces cellular toxicity. Proc Natl Acad Sci USA 2010,107(17),7710-7715","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=142","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.08.011]","volume":"169","author":"Eggers C.","year":"2019","unstructured":"Eggers C.; Fujitani M.; Kato R.; Smid S.; Novel cannabis flavonoid, cannflavin A displays both a hormetic and neuroprotective profile against amyloid &#x3B2;-mediated neurotoxicity in PC12 cells: Comparison with geranylated flavonoids, mimulone and diplacone. Biochem Pharmacol 2019,169","journal-title":"Biochem Pharmacol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3389\/fonc.2019.00660","volume":"9","author":"Moreau M.","year":"2019","unstructured":"Moreau M.; Ibeh U.; Decosmo K.; Bih N.; Yasmin-Karim S.; Toyang N.; Lowe H.; Ngwa W.; Flavonoid derivative of cannabis demonstrates therapeutic potential in preclinical models of metastatic pancreatic cancer. Front Oncol 2019,9,660","journal-title":"Front Oncol"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1055\/s-0043-122240","volume":"84","author":"Lewis M.A.","year":"2018","unstructured":"Lewis M.A.; Russo E.B.; Smith K.M.; Pharmacological foundations of cannabis chemovars. Planta Med 2018,84(4),225-233","journal-title":"Planta Med"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/j.1476-5381.2011.01238.x","volume":"163","author":"Russo E.B.","year":"2011","unstructured":"Russo E.B.; Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 2011,163(7),1344-1364","journal-title":"Br J Pharmacol"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/bs.apha.2017.03.004","volume":"80","author":"Russo E.B.","year":"2017","unstructured":"Russo E.B.; Marcu J.; Cannabis pharmacology: the usual suspects and a few promising leads. Adv Pharmacol 2017,80,67-134","journal-title":"Adv Pharmacol"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1089\/can.2019.0016","volume":"4","author":"Santiago M.","year":"2019","unstructured":"Santiago M.; Sachdev S.; Arnold J.C.; McGregor I.S.; Connor M.; Absence of entourage: terpenoids commonly found in cannabis sativa do not modulate the functional activity of \u03949-THC at Human CB1 and CB2 receptors. Cannabis Cannabinoid Res 2019,4(3),165-176","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1515\/znc-2014-4135","volume":"71","author":"Porres-Mart&#xED;nez M.","year":"2016","unstructured":"Porres-Mart&#xED;nez M.; Gonz&#xE1;lez-Burgos E.; Carretero M.E.; G&#xF3;mez-Serranillos M.P.; In vitro neuroprotective potential of the monoterpenes &#x3B1;-pinene and 1,8-cineole against H2O2-induced oxidative stress in PC12 cells. Z Natforsch C J Biosci 2016,71(7-8),191-199","journal-title":"Z Natforsch C J Biosci"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.ejmech.2017.10.017","volume":"143","author":"Shanmuganathan B.","year":"2018","unstructured":"Shanmuganathan B.; Suryanarayanan V.; Sathya S.; Narenkumar M.; Singh S.K.; Ruckmani K.; Pandima Devi K.; Anti-amyloidogenic and anti-apoptotic effect of &#x3B1;-bisabolol against A&#x3B2; induced neurotoxicity in PC12 cells. Eur J Med Chem 2018,143,1196-1207","journal-title":"Eur J Med Chem"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1271\/bbb.120378","volume":"76","author":"Nagamatsu R.","year":"2012","unstructured":"Nagamatsu R.; Mitsuhashi S.; Shigetomi K.; Ubukata M.; Cleavage of &#x3B1;-dicarbonyl compounds by terpene hydroperoxide. Biosci Biotechnol Biochem 2012,76(10),1904-1908","journal-title":"Biosci Biotechnol Biochem"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.cbi.2016.11.015","volume":"261","author":"Santos N.A.G.","year":"2017","unstructured":"Santos N.A.G.; Martins N.M.; Sisti F.M.; Fernandes L.S.; Ferreira R.S.; de Freitas O.; Santos A.C.; The cannabinoid beta-caryophyllene (BCP) induces neuritogenesis in PC12 cells by a cannabinoid-receptor-independent mechanism. Chem Biol Interact 2017,261,86-95","journal-title":"Chem Biol Interact"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3233\/JAD-140921","volume":"42","author":"Cheng D.","year":"2014","unstructured":"Cheng D.; Spiro A.S.; Jenner A.M.; Garner B.; Karl T.; Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer\u2019s disease transgenic mice. J Alzheimers Dis 2014,42(4),1383-1396","journal-title":"J Alzheimers Dis"},{"key":"ref=153","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.102935]","volume":"88","author":"Jeyakumar M.","year":"2019","unstructured":"Jeyakumar M.; Sathya S.; Gandhi S.; Tharra P.; Suryanarayanan V.; Singh S.K.; Baire B.; Pandima Devi K.; &#x3B1;-bisabolol &#x3B2;-D-fucopyranoside as a potential modulator of &#x3B2;-amyloid peptide induced neurotoxicity: An in vitro","journal-title":"Bioorg Chem"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1248\/bpb.b19-00495","volume":"43","author":"Shin M.","year":"2020","unstructured":"Shin M.; Liu Q.F.; Choi B.; Shin C.; Lee B.; Yuan C.; Song Y.J.; Yun H.S.; Lee I-S.; Koo B-S.; Cho K.S.; Neuroprotective effects of limonene (+) against A&#x3B2;42-induced neurotoxicity in a Drosophila model of Alzheimer\u2019s disease. Biol Pharm Bull 2020,43(3),409-417","journal-title":"Biol Pharm Bull"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1089\/can.2016.0008","volume":"1","author":"Moreno-Sanz G.","year":"2016","unstructured":"Moreno-Sanz G.; Can you pass the acid test? critical review and novel therapeutic perspectives of \u03949-Tetrahydrocannabinolic acid A. Cannabis Cannabinoid Res 2016,1(1),124-130","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref=156","doi-asserted-by":"publisher","DOI":"10.1177\/2042098619846993]","volume":"102","author":"Hillen J.B.","year":"2019","unstructured":"Hillen J.B.; Soulsby N.; Alderman C.; Caughey G.E.; Safety and effectiveness of cannabinoids for the treatment of neuropsychiatric symptoms in dementia: a systematic review. Ther Adv Drug Saf 2019,102","journal-title":"Ther Adv Drug Saf"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"301","DOI":"10.9758\/cpn.2017.15.4.301","volume":"15","author":"Lim K.","year":"2017","unstructured":"Lim K.; See Y.M.; Lee J.; A systematic review of the effectiveness of medical cannabis for psychiatric, movement and neurodegenerative disorders. Clin Psychopharmacol Neurosci 2017,15(4),301-312","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref=158","first-page":"1245","volume":"63","author":"Carroll CB","year":"2004","unstructured":"Carroll CB; Bain PG; Teare L; Liu X; Joint C; Wroath C; Parkin S.G; Fox P; Wright D; Hobart J; Zajicek, JP Cannabis for dyskinesia in parkinson disease: a randomized double-blind crossover study neurology 2004,63,1245-1250"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881114550355","volume":"28","author":"Chagas M.H.","year":"2014","unstructured":"Chagas M.H.; Zuardi A.W.; Tumas V.; Pena-Pereira M.A.; Sobreira E.T.; Bergamaschi M.M.; dos Santos A.C.; Teixeira A.L.; Hallak J.E.; Crippa J.A.; Effects of cannabidiol in the treatment of patients with Parkinson\u2019s disease: an exploratory double-blind trial. J Psychopharmacol (Oxford) 2014,28(11),1088-1098","journal-title":"J Psychopharmacol (Oxford)"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/bs.pmbts.2019.06.005","volume":"167","author":"Elsaid S.","year":"2019","unstructured":"Elsaid S.; Kloiber S.; Le Foll B.; Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings. Prog Mol Biol Transl Sci 2019,167,25-75","journal-title":"Prog Mol Biol Transl Sci"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3233\/JAD-150915","volume":"51","author":"Shelef A.","year":"2016","unstructured":"Shelef A.; Barak Y.; Berger U.; Paleacu D.; Tadger S.; Plopsky I.; Baruch Y.; Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: an-open label, add-on, pilot study. J Alzheimers Dis 2016,51(1),15-19","journal-title":"J Alzheimers Dis"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","volume":"263","author":"L&#xF3;pez-Send&#xF3;n Moreno J.L.","year":"2016","unstructured":"L&#xF3;pez-Send&#xF3;n Moreno J.L.; Garc&#xED;a Caldentey J.; Trigo Cubillo P.; Ruiz Romero C.; Garc&#xED;a Ribas G.; Alonso Arias M.A.A.; Garc&#xED;a de Y&#xE9;benes M.J.; Tol&#xF3;n R.M.; Galve-Roperh I.; Sagredo O.; Valdeolivas S.; Resel E.; Ortega-Gutierrez S.; Garc&#xED;a-Bermejo M.L.; Fern&#xE1;ndez Ruiz J.; Guzm&#xE1;n M.; Garc&#xED;a de Y&#xE9;benes Prous J.; A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington\u2019s disease. J Neurol 2016,263(7),1390-1400","journal-title":"J Neurol"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"8762","DOI":"10.1523\/JNEUROSCI.0708-19.2019","volume":"39","author":"Hudson R.","year":"2019","unstructured":"Hudson R.; Renard J.; Norris C.; Rushlow W.J.; Laviolette S.R.; Cannabidiol counteracts the psychotropic side-effects of \u03949-tetrahydrocannabinol in the ventral hippocampus through bidirectional control of ERK1\u20132 phosphorylation. J Neurosci 2019,39(44),8762-8777","journal-title":"J Neurosci"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3389\/fpsyt.2013.00130","volume":"4","author":"Niesink R.J.M.","year":"2013","unstructured":"Niesink R.J.M.; van Laar M.W.; Does cannabidiol protect against adverse psychological effects of THC? Front Psychiatry, 2013,4,130-130","journal-title":"Front Psychiatry,"},{"key":"ref=165","unstructured":"OPAS\/OMS Brasil. Dem&#xEA;ncia: n&#xFA;mero de pessoas afetadas triplicar&#xE1; nos pr&#xF3;ximos 30 anos.,  https:\/\/www.paho.org\/bra\/index.php? option=com_content"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/183955","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/183955\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/183955","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T11:56:40Z","timestamp":1645963000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/183955\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":165,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x18666200720172624","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-05-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}